SCHEMBL1314441

SCHEMBL1314441

O=CC1C(=O)Nc2ccc(F)cc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 4/20 0.40
DRD2 P14416 1/20 0.38
DRD1 P21728 1/20 0.38
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
ADRA1A P35348 1/20 0.38
HTR6 P50406 1/20 0.38
MAPT P10636 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C19 P33261 1/20 0.37
HDAC1 Q13547 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA4 P22748 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
NTRK1 P04629 1/20 0.36
LRRK2 Q5S007 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29954713 0.86 HTR7 (0.36) HTR7MAPTCYP1A2CYP2C19LRRK2
SCHEMBL29952427 0.79 EPHX2 (0.40) MAPTCYP1A2CYP2C19CA12CA1
SCHEMBL29953205 0.79 PGR (0.43) HTR2CMAPTCYP1A2CYP2C19KMT2A
SCHEMBL29954649 0.79 TP53 (0.46) MAPTCA12CA1CA2CA4
SCHEMBL29951858 0.76 MAOA (0.48) MAPTCA12CA1CA2CA4
SCHEMBL29955187 0.76 PIM1 (0.39) MAPTKMT2APIM1
SCHEMBL29956445 0.76 SMN1; SMN2 (0.40) MAPTKMT2APIM1PIM2
SCHEMBL24112727 0.75 PGR (0.53) HTR7DRD2DRD1HTR2AHTR2C
SCHEMBL2263637 0.75 PGR (0.53) HTR7DRD2DRD1HTR2AHTR2C
SCHEMBL23869671 0.75 HTR7 (0.39) HTR7DRD2DRD1HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
US-8846953-B2 Processes for the preparation of 3-(pyrrol-2-yl)methylene)-2-pyrrolones using 2-silyloxy-pyrroles SCINOPHARM TAIWAN, LTD. (TW) 2014-09-30 US disclosed
US-8846953-B2 Processes for the preparation of 3-(pyrrol-2-yl)methylene)-2-pyrrolones using 2-silyloxy-pyrroles SCINOPHARM TAIWAN, LTD. (TW) 2014-09-30 US disclosed
US-20130190512-A1 PROCESSES FOR THE PREPARATION OF 3-(PYRROL-2-YL)METHYLENE)-2-PYRROLONES USING 2-SILYLOXY-PYRROLES SCINOPHARM TAIWAN, LTD. (TW) 2013-07-25 US disclosed
US-20130190512-A1 PROCESSES FOR THE PREPARATION OF 3-(PYRROL-2-YL)METHYLENE)-2-PYRROLONES USING 2-SILYLOXY-PYRROLES SCINOPHARM TAIWAN, LTD. (TW) 2013-07-25 US disclosed
WO-2012058780-A1 PROCESSES FOR THE PREPARATION OF 3-(PYRROL-2-YL)METHYLENE)-2-PYRROLONES USING 2-SILYLOXY-PYRROLES SCINOPHARM (KUNSHAN) BIOCHEMICAL TECHNOLOGY CO., LTD. (CN) 2012-05-10 WO disclosed
WO-2012059941-A1 PROCESS FOR PREPARATION OF SUNITINIB MALATE AND SALTS THEREOF IND-SWIFT LABORATORIES LIMITED (IN) 2012-05-10 WO disclosed
US-20110275689-A1 Preparation of 3-Pyrrole Substituted 2-Indolinone Derivatives GENERICS [UK] LIMITED (GB) 2011-11-10 US disclosed
US-20110275689-A1 Preparation of 3-Pyrrole Substituted 2-Indolinone Derivatives GENERICS [UK] LIMITED (GB) 2011-11-10 US disclosed
US-20110275689-A1 Preparation of 3-Pyrrole Substituted 2-Indolinone Derivatives GENERICS [UK] LIMITED (GB) 2011-11-10 US disclosed
WO-2011128699-A2 NOVEL PROCESS GENERICS [UK] LIMITED (GB) 2011-10-20 WO disclosed
CN-102137842-A Preparation of 3-pyrrole substituted 2-indolinone derivatives GENERICS UK LTD 2011-07-27 CN disclosed
EP-2318364-A2 PREPARATION OF 3-PYRROLE SUBSTITUTED 2-INDOLINONE DERIVATIVES Generics [UK] Limited (GB) 2011-05-11 EP disclosed
WO-2010001167-A2 NOVEL PROCESS GENERICS [UK] LIMITED (GB) 2010-01-07 WO disclosed
WO-2010001167-A2 NOVEL PROCESS GENERICS [UK] LIMITED (GB) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130190512-A1 PROCESSES FOR THE PREPARATION OF 3-(PYRROL-2-YL)METHYLENE)-2-PYRROLONES USING 2-SILYLOXY-PYRROLES SKP2, SDHA, MDH2 HTR7 3018/4885DRD2 3653/4885DRD1 4090/4885
US-20110275689-A1 Preparation of 3-Pyrrole Substituted 2-Indolinone Derivatives CDC25C, PYCR1, ALDH18A1 HTR7 1799/4885DRD2 1060/4885DRD1 655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.